标题
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
作者
关键词
-
出版物
Cancers
Volume 7, Issue 2, Pages 930-949
出版商
MDPI AG
发表日期
2015-05-26
DOI
10.3390/cancers7020816
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer
- (2016) Gerald S. Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
- (2015) A. Song et al. CLINICAL CANCER RESEARCH
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
- (2015) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
- (2015) S. Schmid et al. LUNG CANCER
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
- (2015) Monika Joshi et al. PLoS One
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
- (2014) A Patnaik et al. BRITISH JOURNAL OF CANCER
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- (2014) Mark G. Kris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reply to A. Soultati et al
- (2014) David Robert Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
- (2014) Sara D. Robinson et al. LUNG CANCER
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
- (2014) Antonio Calles et al. Molecular Oncology
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C
- (2014) J. C. Hunter et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
- (2013) R. G. Liao et al. CANCER RESEARCH
- Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitorsin vitroandin vivo
- (2013) Makito Suzuki et al. CANCER SCIENCE
- Characteristics of Lung Cancers Harboring NRAS Mutations
- (2013) K. Ohashi et al. CLINICAL CANCER RESEARCH
- Dramatic Response Induced by Vemurafenib in aBRAFV600E-Mutated Lung Adenocarcinoma
- (2013) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Clinical Response to a BRAF Inhibitor in a Patient With a BRAF L597R–Mutated Melanoma
- (2013) Philippe Bahadoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- New Targetable Oncogenes in Non–Small-Cell Lung Cancer
- (2013) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- (2013) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
- (2013) Oliver Gautschi et al. Journal of Thoracic Oncology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib
- (2013) Oliver Gautschi et al. LUNG CANCER
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
- (2013) Aria Vaishnavi et al. NATURE MEDICINE
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- A High-Dimensional, Deep-Sequencing Study of Lung Adenocarcinoma in Female Never-Smokers
- (2013) Sang Cheol Kim et al. PLoS One
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
- (2013) Kurtis D. Davies et al. PLoS One
- Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
- (2013) M. A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
- (2013) Georgia Konstantinidou et al. Cancer Discovery
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer
- (2012) Hye Ryun Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
- (2012) Rebecca S. Heist et al. Journal of Thoracic Oncology
- A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
- (2012) Oliver Gautschi et al. Journal of Thoracic Oncology
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling
- (2011) J. E. Chaft et al. MOLECULAR CANCER THERAPEUTICS
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
- (2010) H. J. Ross et al. CLINICAL CANCER RESEARCH
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
- (2010) M. S. Gordon et al. CLINICAL CANCER RESEARCH
- Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
- (2010) Yihua Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
- (2010) Lingxiang Liu et al. Journal of Thoracic Oncology
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients
- (2010) Carlos Camps et al. LUNG CANCER
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations
- (2009) G. Konstantinidou et al. CANCER RESEARCH
- Targeting the RET Pathway in Thyroid Cancer
- (2009) S. A. Wells et al. CLINICAL CANCER RESEARCH
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
- (2009) Michèle Beau-Faller et al. Journal of Thoracic Oncology
- Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
- (2009) Aristea Kalikaki et al. LUNG CANCER
- PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers
- (2009) Guang Jin et al. LUNG CANCER
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma
- (2008) J. L. Marks et al. CANCER RESEARCH
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now